Ameriprise’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.02B Sell
7,287,230
-513,188
-7% -$71.9M 0.24% 96
2025
Q4
$957M Buy
7,800,418
+652,013
+9% +$79.2M 0.22% 97
2025
Q3
$794M Buy
7,148,405
+400,002
+6% +$45.5M 0.18% 112
2025
Q2
$748M Buy
6,748,403
+5,392,191
+398% +$574M 0.18% 114
2025
Q1
$152M Buy
1,356,212
+25,659
+2% +$2.65M 0.04% 394
2024
Q4
$123M Sell
1,330,553
-561,251
-30% -$50.5M 0.03% 474
2024
Q3
$159M Sell
1,891,804
-101,451
-5% -$7.74M 0.04% 393
2024
Q2
$137M Buy
1,993,255
+367,878
+23% +$24.6M 0.04% 411
2024
Q1
$119M Buy
1,625,377
+36,246
+2% +$2.79M 0.03% 475
2023
Q4
$129M Sell
1,589,131
-114,652
-7% -$8.92M 0.04% 437
2023
Q3
$128M Buy
1,703,783
+115,189
+7% +$8.86M 0.04% 407
2023
Q2
$122M Sell
1,588,594
-90,181
-5% -$7.19M 0.04% 441
2023
Q1
$139M Buy
1,678,775
+204,240
+14% +$16.9M 0.05% 394
2022
Q4
$127M Sell
1,474,535
-137,378
-9% -$10.9M 0.04% 410
2022
Q3
$100M Sell
1,611,913
-52,441
-3% -$3.31M 0.04% 457
2022
Q2
$102M Sell
1,664,354
-172,999
-9% -$10.7M 0.04% 473
2022
Q1
$105M Buy
1,837,353
+398,731
+28% +$25.5M 0.03% 518
2021
Q4
$102M Buy
1,438,622
+238,965
+20% +$16.5M 0.03% 566
2021
Q3
$83.8M Sell
1,199,657
-2,587,398
-68% -$182M 0.03% 569
2021
Q2
$261M Sell
3,787,055
-157,445
-4% -$10.5M 0.08% 258
2021
Q1
$255M Sell
3,944,500
-632,551
-14% -$40.8M 0.08% 240
2020
Q4
$268M Sell
4,577,051
-59,296
-1% -$3.58M 0.1% 229
2020
Q3
$291M Buy
4,636,347
+141,898
+3% +$9.84M 0.12% 189
2020
Q2
$346M Sell
4,494,449
-1,727,247
-28% -$132M 0.15% 146
2020
Q1
$468M Sell
6,221,696
-942,965
-13% -$65.2M 0.25% 84
2019
Q4
$466M Sell
7,164,661
-193,192
-3% -$12.6M 0.19% 110
2019
Q3
$466M Sell
7,357,853
-728,023
-9% -$47.6M 0.21% 101
2019
Q2
$547M Buy
8,085,876
+503,477
+7% +$33.1M 0.24% 83
2019
Q1
$493M Buy
7,582,399
+3,714
+0% +$247K 0.23% 84
2018
Q4
$474M Buy
7,578,685
+1,381,794
+22% +$96.6M 0.24% 86
2018
Q3
$487M Sell
6,196,891
-87,350
-1% -$6.6M 0.17% 126
2018
Q2
$445M Buy
6,284,241
+996,408
+19% +$70.4M 0.2% 107
2018
Q1
$399M Buy
5,287,833
+151,184
+3% +$12M 0.18% 124
2017
Q4
$368M Sell
5,136,649
-369,059
-7% -$28M 0.17% 135
2017
Q3
$446M Buy
5,505,708
+2,524,657
+85% +$193M 0.21% 105
2017
Q2
$211M Sell
2,981,051
-675,200
-18% -$44.9M 0.11% 203
2017
Q1
$248M Buy
3,656,251
+831,432
+29% +$58.5M 0.13% 171
2016
Q4
$202M Buy
2,824,819
+360,343
+15% +$26.8M 0.11% 193
2016
Q3
$195M Sell
2,464,476
-1,447,777
-37% -$118M 0.11% 192
2016
Q2
$326M Sell
3,912,253
-441,422
-10% -$39.2M 0.19% 115
2016
Q1
$400M Sell
4,353,675
-1,102,529
-20% -$99.4M 0.24% 90
2015
Q4
$550M Sell
5,456,204
-1,562,303
-22% -$163M 0.32% 66
2015
Q3
$688M Sell
7,018,507
-624,593
-8% -$69.4M 0.43% 47
2015
Q2
$895M Sell
7,643,100
-1,001,910
-12% -$109M 0.51% 37
2015
Q1
$848M Sell
8,645,010
-318,442
-4% -$32.3M 0.49% 40
2014
Q4
$845M Sell
8,963,452
-5,336,100
-37% -$552M 0.49% 36
2014
Q3
$1.52B Sell
14,299,552
-3,715,590
-21% -$364M 0.92% 10
2014
Q2
$1.49B Sell
18,015,142
-691,833
-4% -$53.9M 0.88% 9
2014
Q1
$1.33B Sell
18,706,975
-1,388,441
-7% -$109M 0.8% 10
2013
Q4
$1.51B Sell
20,095,416
-1,486,394
-7% -$103M 0.91% 7
2013
Q3
$1.36B Sell
21,581,810
-284,797
-1% -$17M 0.89% 8
2013
Q2
$1.12B Buy
+21,866,607
New +$1.14B 0.78% 12

Other funds holding GILD

Ameriprise's GILD Position: Q1 2026 in Review

Ameriprise reduced its Gilead Sciences (GILD) stake by 6.6% in Q1 2026, selling an estimated $71.9M and leaving 7,287,230 shares worth $1.02B. The position accounts for 0.24% of the portfolio, ranked #96.

Ameriprise first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.52B in Q3 2014. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Ameriprise held 7,287,230 shares of Gilead Sciences worth $1.02B as of Q1 2026.
  • Ameriprise sold 513,188 Gilead Sciences shares in Q1 2026, an estimated $71.9M.
  • Gilead Sciences made up 0.24% of Ameriprise's portfolio in Q1 2026, its #96 holding.
  • Ameriprise first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Ameriprise's Gilead Sciences position peaked at $1.52B in Q3 2014.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.